Dipeptidyl Peptidase-4 Inhibitor Versus Sodium-Glucose Cotransporter-2 Inhibitor in the Management of Type 2 Diabetes
نویسندگان
چکیده
منابع مشابه
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have been carried out revealing its ability to not only improve metabolic control but also ameliorate ...
متن کاملEuglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
More than 10 million Canadians are currently living with diabetes.1 Of those, 90% have type 2 diabetes mellitus (T2DM).1 Recently launched oral medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors were approved by the US Food and Drug Administration (FDA) in 2013 for treating T2DM.2 Approval by Health Canada was granted in 2014.3 Treatment with SGLT2 inhibitors (canagliflozin,...
متن کاملDapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a growing worldwide epidemic. Patients face lifelong therapy to control hyperglycemia and prevent the associated complications. There are many medications, with varying mechanisms, available for the treatment of T2DM, but almost all target the declining insulin sensitivity and secretion that are associated with disease progression. Medications with such insuli...
متن کاملThe Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
The vascular endothelial function is impaired in the very early stage of atherosclerosis in diabetic patients. The goal of this study was to identify the mechanism underlying the improvement in vascular endothelial function by sitagliptin in type 2 diabetes mellitus patients. This study was an open-labeled prospective observational single arm trial. Forty patients were treated with 50 mg of sit...
متن کاملSodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
Type 2 diabetes mellitus (T2DM) is a progressive and multifactorial cardiometabolic disorder. Almost half of adults with diabetes fail to achieve their recommended glucose control target. This has prompted some clinicians to advocate the use of more intensive initial therapy, including the use of combination therapy to target multiple physiologic defects in diabetes with the goal of achieving a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Endocrinology and Metabolism
سال: 2019
ISSN: 1923-2861,1923-287X
DOI: 10.14740/jem609